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Abstract
Background: The conversion of one cell type into another has been suggested to be, at the
molecular level, the consequence of change(s) in the expression level of key developmental genes.
Myoblasts have the ability to differentiate either to skeletal muscle or osteogenic lineage depending
of external stimuli. Extracellular matrix (ECM) has been shown to be essential for skeletal muscle
differentiation, through its direct interaction with myoblasts' cell receptors. We attempt to address
if ECM also plays a role in the osteogenic differentiation of skeletal muscle cells.
Results: Inhibition of proteoglycan sulfation by sodium chlorate in myoblast cultures strongly
affects ECM synthesis and deposition and induces the expression of the osteogenic lineage markers
alkaline phosphatase (ALP) and osteocalcin in mononuclear cells. Induction of ALP by sodium
chlorate does not affect the expression of specific muscle determination transcription factors, such
as MyoD and Myf-5, in the same cells. The osteogenic transcription factor Cbfa-1 expression is also
unaffected. Induction of ALP is not inhibited by a soluble form of BMP receptor IA. This suggests
that the deviation of the myogenic pathway of C2C12 myoblasts into the osteogenic lineage by
inhibitors of proteoglycan sulfation is BMP-2 independent. The increase of osteogenic markers
expression can be totally prevented by an exogenous ECM. Interestingly, a similar BMP-2-
independent ALP activity induction can be observed in myoblasts cultured on an ECM previously
synthesized by BMP-2 treated myoblasts. Under in vivo conditions of increased ECM turn-over and
deposition, as in the mdx dystrophic muscle and during skeletal muscle regeneration, an induction
and relocalization of ALP is observed in a subpopulation of skeletal muscle fibers, whereas in
normal skeletal muscle, ALP expression is restricted to blood vessels and some endomysial
mononuclear cells.
Conclusion: These results suggest that signals arising from the ECM induce the expression of
osteogenic markers in muscle cells by a mechanism independent of BMP-2 and without affecting
the expression of key muscle or osteogenic determination genes. An induction and relocalization
of ALP is also observed in mdx and regenerating skeletal muscles, in vivo conditions of increased
muscle ECM deposition or turnover.
Published: 5 October 2009
BMC Cell Biology 2009, 10:73 doi:10.1186/1471-2121-10-73
Received: 3 July 2009
Accepted: 5 October 2009
This article is available from: http://www.biomedcentral.com/1471-2121/10/73
© 2009 Osses et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
Page 2 of 17
(page number not for citation purposes)
Background
Understanding the cellular and molecular basis of cell-
determination and terminal differentiation is important
as to gain insight into the mechanisms of normal develop-
ment and, potentially, for the achievement of successful
stem cell-based therapies. The observation that embryo-
logical commitments can be reversed or erased under cer-
tain circumstances, in a phenomenon known as
metaplasia [1], is particularly interesting.
Skeletal muscle cells are a helpful model for studying cell
commitment and differentiation. During skeletal muscle
development, fusion of mononuclear myoblasts to form
multinucleated myotubes is a central event. This process is
partially controlled by the sequential expression of some
regulatory proteins, the myogenic regulatory transcription
factors (MRFs) of the MyoD family (MyoD, Myf-5, myo-
genin and MRF4). Forced expression of MRFs in different
mesenchymatic cell lines can induce their transdifferenti-
ation into skeletal muscle [2,3]. The expression and activ-
ity of these master genes are regulated by several
polypeptide growth factors as well as by retinoic acid [4-
7]. The presence of extracellular matrix (ECM) is critical
for a proper skeletal muscle differentiation. For instance,
inhibitors of collagen synthesis have been shown to
inhibit myoblast differentiation [8,9]. Addition of either
RGDS peptides or antibodies against integrin receptor to
myoblast cultures has also a strong inhibitory effect on
muscle differentiation [10,11]. We have shown that
inhibitors of proteoglycan synthesis, such as sodium chlo-
rate and β-D-xylosides, produce a strong inhibition of
ECM assembly that is followed by repression of skeletal
muscle differentiation [11,12], even though the MRF
myogenin is expressed and properly localized at the
nuclei. This inhibition can be totally rescued by the addi-
tion of an exogenous ECM, suggesting that the ECM and
its receptors provide an appropriate and permissive envi-
ronment for lineage-specific cell differentiation [11].
Studies on stem cells transplantation have highlighted the
role of local tissue signals for specific cell-type determina-
tion, but the relative contribution of intrinsic or genetic
signals and extrinsic or ECM signals in cell behavior are
not completely understood. Within skeletal muscle tissue
specific cells exhibit apparent stem-cell like plasticity [13-
16]. BMP-2 treatment of the mouse myoblast cell line
C2C12 [17] and muscle satellite cells isolated from adult
mice [18] inhibits myotube formation and induces the
expression of alkaline phosphatase activity (ALP) and
osteocalcin, changing their differentiation pathway into
the osteoblastic lineage. Interestingly, in several muscular
diseases [19-21] and animal models for skeletal muscle
dystrophy [22], the level of ALP is increased. We have
studied microenvironmental changes of skeletal muscle in
the mdx mouse, an animal model of Duchenne muscular
dystrophy (DMD) [23], finding an important increase in
the amount of ECM proteoglycans present at endomy-
sium and perimysium [24-26]. We have also found an up-
regulation of proteoglycans during the process of damage-
induced muscle regeneration [27,28].
In this paper, we show that inhibition of proteoglycan sul-
fation by sodium chlorate in myoblast cultures induces
the expression of osteogenic lineage markers and that this
can be prevented by the presence of an exogenous ECM.
ECM synthesized by BMP-2 treated-myoblasts can also
induce ALP in myoblasts. This induction is mediated by
BMP-2 independent mechanisms in both cases. Expres-
sion of osteogenic markers does not affect the expression
of muscle commitment MRFs or the osteogenic determi-
nation gene Cbfa-1. We finally show that in mdx  and
regenerating skeletal muscles, in vivo conditions of
increased muscle ECM deposition or turnover, an induc-
tion and relocalization of ALP was found.
Results
Inhibition of Proteoglycan Synthesis in Myoblasts Induces 
the Expression of Osteogenic Lineage Markers
Sodium chlorate is a specific inhibitor of proteoglycan
sulfation which does not affect cell protein or DNA con-
tent [12,29]. Table 1 shows that in cultures of the clonal
myoblastic cell line C2C12, sulfation of proteoglycans is
strongly inhibited by sodium chlorate 30 mM. We have
shown that sodium chlorate treatment affects the deposi-
tion of different ECM components such as laminin,
fibronectin and ECM proteoglycans [11,12]. Cultures of
control C2C12 myoblasts induced to differentiate and
Table 1: Effect of Chlorate on [35S]-SO4 Incorporation into 
Proteoglycans and Glycosaminoglycans in C2C12 Myoblasts.
cpm/mg DNA
Control Chlorate
Medium
Proteoglycans 3950 ± 520 240 ± 40
Glycosaminoglycans 1990 ± 570 520 ± 110
Extracts
Proteoglycans 11180 ± 550 820 ± 20
Glycosaminoglycans 3820 ± 460 290 ± 100
C2C12 cells were incubated for 48 hours with 30 mM sodium 
chlorate. Sulfate incorporation during the last 18 hours was measured 
in medium and detergent extracts. [35S]Sulfate radioactivity for total 
(proteoglycans plus glycosaminoglycans) and trichloroacetic acid-
precipitated material (proteoglycans) samples, spotted on filters 
containing the cationic detergent cetyl pyridinium chloride (CPC), 
was measured with liquid scintillation counting. DNA content was 
measured in same aliquots of detergent extracts (13.3 μg/μl for 
control and 18.0 μg/μl for chlorate treated cells). The specific activity 
values correspond to the means ± SD obtained from three different 
plates.BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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stained with anti-perlecan antibody show a bright and
fibrillar specific staining of this ECM heparan sulfate pro-
teoglycan (Figure 1A, top). Conversely, sodium chlorate
treatment of parallel cultures almost abolished the perle-
can staining (Figure 1A, bottom). Figure 1A also shows that
when myoblasts were induced to differentiate in the pres-
ence of sodium chlorate, a marked inhibitory effect on
both the number and length of the myotubes was
observed, with a concomitant increment in the number of
remaining mononuclear cells (around 50% of increase,
data not shown). Due to the known capacity of C2C12
cells to generate cells from different lineages under special
culture conditions, the expression of ALP, an early marker
of osteogenic differentiation, was evaluated in cultures
treated with sodium chlorate. ALP activity was determined
during myogenic differentiation in the presence or
absence of ECM as a consequence of sodium chlorate
treatment. Figure 1B shows that around a 100% of
increase in ALP activity is observed in myoblasts under
sodium chlorate treatment as compared to control cul-
tures at day 8 of differentiation. Under similar conditions,
the induction of creatine kinase (CK) activity, a skeletal
muscle differentiation marker, was diminished to less
than 50% of control values by the absence of ECM (Figure
1C). Figure 1D shows that both the induction of ALP and
the inhibition of CK were totally dependent of the con-
centration of sodium chlorate present in the differentia-
tion medium. To evaluate if the inductive effect on ALP
activity by sodium chlorate treatment was a particular
phenomenon of this clonal cell line, primary cultures of
rat muscle myoblasts were prepared and incubated under
differentiation conditions [30]. Figure 1E (top panel)
shows that ALP activity was inhibited 6 days after the cul-
ture cells were induced to differentiate. In contrast, cul-
tures in the presence of sodium chlorate maintained high
values of ALP activity. High values of ALP, probably aris-
ing from intramuscular connective tissue cells, have been
previously observed in primary cultures of skeletal muscle
cells under growth conditions [31]. Bottom panel of Fig-
ure 1E shows that primary cultures of muscle cells differ-
entiate appropriately in vitro as evaluated as the induction
of CK activity, which was inhibited by sodium chlorate
treatment as was seen in C2C12 myoblasts.
To further characterize the phenotype of myoblast differ-
entiation in the presence of sodium chlorate, the expres-
sion of the specific osteogenic differentiation marker
osteocalcin was studied by RT-PCR. Figure 1F shows that
sodium chlorate treatment of C2C12 cells under differen-
tiation conditions induces the expression of osteocalcin
mRNA, indicating their osteogenic nature. The same Fig-
ure shows, as a positive control, the induction of osteocal-
cin by recombinant BMP-2 as has been previously
described [17,32].
To visualize in which cell type the observed induction of
ALP activity was localized, C2C12 cultures were induced
to differentiate in the presence or absence of the sulfation
inhibitor and stained for ALP activity. As shown in Figure
2A only mononuclear cells are expressing ALP activity. A
quantitative analysis indicates that under differentiation
conditions in the presence of sodium chlorate, almost
50% of the total mononuclear cells expressed ALP activity
(Figure 2B). When these mononuclear cells were isolated,
replated and maintained under growth conditions, ALP
activity remained higher in cultures that were treated with
sodium chlorate as compared to cells isolated from con-
trol cultures. Induction of ALP activity by BMP-2 treat-
ment is shown as a positive control in the same Figure.
These results suggest that the inhibition of proteoglycan
sulfation by sodium chlorate affects ECM assembly and
induces the expression of osteogenic markers in mononu-
clear muscle cells concomitant with an inhibition of the
process of skeletal muscle differentiation.
Induction of ALP Activity by Inhibitors of Proteoglycan 
Sulfation Does Not Affect the Expression of Specific 
Muscle Transcription Factors of Commitment
It is well known that skeletal muscle differentiation is
under the control of MRFs [33]. Proliferative C2C12
myoblasts express the muscle determination factors
MyoD and Myf5. Under serum deprival conditions myo-
genin expression is triggered and terminal skeletal muscle
differentiation is induced. To evaluate if the cells express-
ing ALP activity did not express MRFs, mononuclear cells
were isolated from cultures after 6 days of differentiation
in the presence of sodium chlorate. Figure 3A shows ALP
activity and localization of MyoD, Myf-5 and myogenin in
monuclear cells. It can be seen that some mononuclear
cells, as recognized in phase contrast visualization co-
express ALP and MyoD or Myf5 (top and middle row).
Quantitative analysis indicates that about 30 to 40 % of
total mononuclear cells express ALP without expression of
Myo or Myf5 (Figure 3B). The same figure shows that
around 20% of the cells express MyoD or Myf5 without
expressing ALP activity but also 20 to 30% of the mono-
nuclear cells co-express ALP activity and MyoD or Myf5.
Isolated mononuclear cells express very little levels of
myogenin, as expected. These results indicate that the
induction of ALP activity under conditions of a deficient
ECM in mononuclear cells is not dependent on a turning
off of the expression of determination MRFs.
We also evaluated the expression of Cbfa-1, an specific
osteogenic determination gene which induces osteoblas-
tic differentiation, by RT-PCR [34,35]. Presence of Cbfa-1
has been observed in myogenic muscle cells derived from
satellite cells as well as C2C12 myoblasts [36,37]. Figure 4
shows low levels of Cbfa-1 expression in myoblasts trig-BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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Inhibition of proteoglycan sulfation induces osteogenic markers expression in C2C12 myoblasts Figure 1
Inhibition of proteoglycan sulfation induces osteogenic markers expression in C2C12 myoblasts. Myoblasts were 
induced to differentiate in the absence (control) or presence of 30 mM sodium chlorate (chlorate) A. Phase contrast micros-
copy (left column) and perlecan indirect immunofluorescent staining (right column) of non-permeabilized cells C2C12 cells at 6 
days of differentiation under control (upper row) and chlorate (lower row) conditions. Bar = 25 μm. B and C. ALP (B) and 
CK (C) activities were measured at different time points after inducing differentiation of C2C12 in control or chlorate condi-
tions. Both enzymatic activities were significantly different in control vs. chlorate (p < 0.0001, unpaired t-test). D. ALP and CK 
measurements at eight days after induction of differentiation of C2C12 cells under different concentrations of sodium chlorate. 
E. ALP (upper panel) and CK (lower panel) activity determinations at day 1 and 6 of differentiation of primary cultures of mus-
cle cells from rat fetal hind limbs under control or chlorate conditions. * = p < 0.001 different from Control d1 (lower panel) 
or Control d1 and Chlorate d6 (upper panel); ** = p < 0.001, different from Control d1 and d6 (One-way Analysis of Variance 
(ANOVA) followed by Tukey-Kramer multiple comparisons test). All the data are presented as Mean ± S.D. of two (E) or 
three (B-D) independent experiments performed in triplicate. F. RT-PCR for Osteocalcin and β-actin performed on RNA 
extracted from C2C12 cells at 6 days of differentiation in the absence or presence of 1 nM BMP-2 or 30 mM sodium chlorate.BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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Under conditions of proteoglycan sulfation inhibition, alkaline phosphatase activity is present in mononuclear skeletal muscle  cells Figure 2
Under conditions of proteoglycan sulfation inhibition, alkaline phosphatase activity is present in mononuclear 
skeletal muscle cells. A. C2C12 cells were induced to differentiate for 6 days in the absence (first column) or presence of 
30 mM sodium chlorate (second column). Remaining mononuclear cells from control (third column) or sodium chlorate 
treated cultures (fourth column) were isolated and grown for 48 hours. C2C12 cells induced to differentiate in the presence of 
5 nM BMP-2 were used as positive control (fifth column). Unpermeabilized cells were fixed and alkaline phosphatase activity 
was visualized as a fluorescent precipitate using ELF-97 detection kit; nuclear staining was performed with 1 μg/ml Hoechst 
33258 (lower row). Phase contrast microscopy is shown in the upper row. Bar = 25 μm. B. Percentage of ALP-positive mono-
nuclear cells in the different experimental conditions described in A. Values correspond to mean ± S.E.M. of 10 different micro-
scopy fields from two independent experiments. ANOVA analysis followed by Tukey-Kramer multiple comparisons test shows 
there are no statistically significant differences when both control or both chlorate conditions (p > 0.05) are compared. All 
other comparisons are significantly different (p < 0.001).BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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Alkaline phosphatase positive mononuclear cells express myogenic regulatory factors Figure 3
Alkaline phosphatase positive mononuclear cells express myogenic regulatory factors. Mononuclear cells were 
isolated from C2C12 cell cultures after 6 days of differentiation in presence of 30 mM sodium chlorate. Permeabilized cells 
were fixed and stained for alkaline phosphatase activity using ELF-97 detection kit and for MRFs using polyclonal anti-mouse 
MyoD, anti-human Myf5 or anti-rat myogenin antibodies. TRITC-conjugated anti-rabbit IgG was used as secondary antibody. 
Symbols represent: arrow, MRF+/ALP+; arrowhead, MRF+/ALP-; diamond, MRF-/ALP+; asterisk, MRF-/ALP-. Bar = 50 μm. B. 
Quantification of single or double labeled cells was performed in 10 independent fields. a, MRF+/ALP+; b, MRF+/ALP-; c, MRF-
/ALP+; MRF-/ALP-. (Mean ± S.D. of two independent experiments).BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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gered to differentiate. Cbfa-1 expression is induced by
BMP-2 but not by sodium chlorate treatment. As a com-
parison the same Figure shows that myogenin is present in
myoblasts induced to differentiate and that it is inhibited
by BMP-2, but is unaffected by sodium chlorate treat-
ment. As mentioned before, the inhibitory effect of
sodium chlorate on skeletal muscle differentiation was
independent of myogenin expression and its nuclear
localization [11,12]. These results indicate that sodium
chlorate treatment of skeletal muscle cells does not affect
the expression of osteogenic or muscle key differentiation
genes.
Induction of ALP Activity by Sodium Chlorate Treatment is 
BMP-2 Independent
To evaluate if the observed induction of ALP in C2C12 by
sodium chlorate was dependent of BMP-2 expression, we
studied the effect on this phenomenon of adding a solu-
ble form of BMP receptor IA (BMPR-IA). Figure 5A shows
that when C2C12 myoblasts were treated with BMP-2,
ALP activity was induced whereas CK activity was strongly
inhibited. Figure 5B shows that the addition of the BMPR-
IA blocked almost completely the induction of ALP activ-
ity produced by BMP-2 with a concomitant induction of
CK activity on the sixth day of differentiation. Figure 5C
shows that 1 μg/ml BMPR-IA, the highest dose studied,
has no effect either on the induction of ALP activity or on
the inhibition of CK by sodium chlorate treatment (Figure
5D). These results suggest that the deviation of the myo-
genic differentiation pathway of C2C12 myoblasts into
the osteogenic lineage by sodium chlorate is BMP-2 inde-
pendent.
Exogenous ECM Prevents Osteogenic Markers Expression 
Induced by Inhibition of Proteoglycan Sulfation
We have previously shown that the inhibitory effect of
sodium chlorate on skeletal muscle differentiation was
the result of an altered deposition of ECM by the muscle
cells as a consequence of inhibition of proteoglycans sul-
fation [11,12]. We now evaluated if it was possible to pre-
vent the induction of ALP activity produced by sodium
chlorate treatment by providing the cells with exogenous
ECM. In the experiments shown in Figure 6, the effect of
ECM gel, a basement membrane-like ECM obtained from
mouse EHS sarcoma, on the induction of ALP activity was
studied. Figure 6A shows that the ECM gel prevented the
induction of ALP activity. This effect was observed by add-
ing the ECM-gel at the beginning of the differentiation
(day 0) or at day 4 of differentiation. Figure 6B shows a
titration of the inhibitory effect of ECM-gel on the induc-
tion of ALP by sodium chlorate. Interestingly, the ECM gel
at higher concentration was able to inhibit ALP activity
below the levels observed for control cells, as shown in
Figure 6B. The inhibitory effect of ECM-gel on the induc-
tion of osteogenic markers as consequence of sodium
chlorate treatment was also observed on the induction of
osteocalcin, as shown in the Figure 6C. This Figure also
shows that co-treatment of myoblasts with BMP-2 and
sodium chlorate augments the effect on osteocalcin
induction, although its enhanced expression could not be
totally prevented by the addition of the ECM-gel. These
results suggest that the induction of osteogenic markers by
inhibition of proteoglycan sulfation can be prevented by
an exogenous ECM.
ECM from BMP-2 Treated Myoblasts Induces ALP Activity 
in muscle cells
The above described experiments suggest that the induc-
tive effect of sodium chlorate on osteogenic markers
expression is likely a consequence of an altered ECM. We
explored then if this ECM modification was specific for
the induction of osteogenic markers expression in muscle
cells or if it would be possible to produce a similar effect
using ECM obtained from BMP-2 treated myoblasts. To
evaluate this point we plated muscle cells over ECM
obtained from cultured myoblasts induced to transdiffer-
entiate by BMP-2 treatment. Figure 7A shows that after
removal of the cells by PBS/EDTA incubation, the ECM of
differentiated myoblasts remained attached to the culture
plates as can be seen by the presence of some ECM com-
ponents. The same is true if myoblasts are treated with
BMP-2 (Figure 7B). The effect of these ECMs on ALP activ-
ity was evaluated by plating C2C12 myoblasts on them
Cbfa-1 expression is not induced by inhibition of proteogly- can sulfation Figure 4
Cbfa-1 expression is not induced by inhibition of pro-
teoglycan sulfation. RNA from C2C12 cells after 6 days of 
differentiation in the absence or presence of 1 nM BMP-2 or 
30 mM sodium chlorate was obtained. After reverse tran-
scription using Oligo-dTs, Cbfa-1, myogenin and β-actin 
cDNAs were amplified using specific primers. The reactions 
were performed within the linear range for both time and 
RNA quantity.BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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Alkaline phosphatase activity induced by inhibition of proteoglycan sulfation is not BMP-2 dependent Figure 5
Alkaline phosphatase activity induced by inhibition of proteoglycan sulfation is not BMP-2 dependent. A. C2C12 
cells were induced to differentiate in the presence of 5 nM BMP-2. ALP (open circles) and CK (closed circles) activity was 
determined as a function of time. The mean ± S.D. of two independent experiments performed in triplicate is presented. B. 
C2C12 cells were induced to differentiate in the presence of 5 nM BMP-2 and different concentrations of soluble BMP recep-
tor IA (BMPR-IAsoluble). ALP (open circles) and CK (closed circles) activity was determined at day 6. Values presented as mean 
± S.D. of two independent experiments performed in triplicate. C2C12 cells were induced to differentiate either in the 
absence (control) or presence of 30 mM sodium chlorate (chlorate) or 1 μg/ml soluble BMP receptor IA (BMPR-IAsoluble). ALP 
(C) and CK (D) activity was determined at day 8 days. The mean ± S.E.M, of two independent experiments performed in trip-
licate is presented. ANOVA analysis followed by Tukey-Kramer multiple comparisons test shows that there are no statistically 
significant differences (p > 0.05) within the control or chlorate conditions. All other comparisons are significantly different (p < 
0.001).BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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Addition of exogenous ECM prevents osteoblastic marker expression induced by inhibition of proteoglycan sulfation Figure 6
Addition of exogenous ECM prevents osteoblastic marker expression induced by inhibition of proteoglycan 
sulfation. A. C2C12 cells were induced to differentiate in the presence of 30 mM sodium chlorate (closed circles). ECM gel 
was added at day 0 (open circles) or at day 4 of differentiation (closed triangles). ALP activity was determined at different time 
points. Data are presented as mean ± S.E.M. of two independent experiments performed in triplicate (p < 0.0001, unpaired t-
test between chlorate and ECM gel addition). B. ALP activity was determined in C2C12 cells induced to differentiate for 8 days 
in the absence (control) or presence of 30 mM sodium chlorate (chlorate) and different ECM gel dilutions were added to the 
cell culture. Data are presented as mean ± S.E.M. of two independent experiments performed in triplicate. * = significantly dif-
ferent from chlorate without and with 1:100 ECM gel, p < 0.05; ** = significantly different from all the other conditions p < 
0.05 (ANOVA followed by Tukey-Kramer multiple comparisons test between chlorate conditions). C. RNA was extracted 
from C2C12 cells after 6 days of differentiation in the presence or absence of 30 mM sodium chlorate, 1 nM BMP-2, and/or 
ECM gel. After reverse transcription using Oligo-dTs the cDNA was amplified using specific primers for osteocalcin and β-
actin.BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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ECM produced by BMP-2 treated myoblasts induces alkaline phosphatase in C2C12 cells Figure 7
ECM produced by BMP-2 treated myoblasts induces alkaline phosphatase in C2C12 cells. A. C2C12 cells were 
induced to differentiate for 6 days. Unpermeabilized cells (E-G) or coverslips after cell removal by EDTA treatment (I-K) were 
stained with anti-fibronectin (FN), anti-laminin (LN) or anti-perlecan (PER) antibodies. H and L show anti-tubulin (TUB) staining 
after permeabilization. FITC-conjugated secondary antibodies were used. Phase contrast microscopy is shown (A-D). Bar = 25 
μm. B. C2C12 cells were induced to differentiate for 6 days in the absence (MTs) or presence of 5 nM BMP-2 (BMP-2). Unper-
meabilized cells (A, D) or ECM (G, J) obtained as described in A were stained with anti-fibronectin antibodies. FITC-conjugated 
secondary antibodies were used. Nuclear staining was performed with 1 μg/ml Hoechst 33258 (B, E, H, K). Phase contrast 
microscopy for cells is shown (C and F) and staining without the primary antibody is shown in I and L. Bar = 25 μm. C. C2C12 
cells were plated on ECM from myotubes (ECM MTs) or BMP-2 treated cells (ECM BMP-2), as described above, and induced 
to differentiate in the absence or presence of 1 μg/ml soluble BMP receptor IA (BMPR-IAsoluble). ALP activity was determined at 
day 6. Data are presented as mean ± S.E.M. of three independent experiments performed in triplicate. * = significantly different 
from the other values, but not between them, p < 0.015 (ANOVA followed by Tukey-Kramer multiple comparisons test).BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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and inducing skeletal muscle differentiation. Figure 7C
shows that myoblasts plated on ECM obtained after BMP-
2 treatment presented a significant increase in ALP activ-
ity. This increase was not prevented by the addition of
BMPR-IA during the differentiation process. This Figure
also shows that when myoblasts were induced to differen-
tiate on ECM isolated from myotubes, there was no induc-
tion of ALP activity. These results suggest that the ECM
synthesized as consequence of BMP-2 treatment of myob-
lasts has the ability to induce ALP activity by a BMP-2
independent mechanism.
Induction and Cellular Relocalization of ALP Activity in a 
Dystrophic Animal Model
It has been shown that human dystrophic muscle presents
an augmented ALP activity [19]. ALP activity was evalu-
ated in control and mdx mouse diaphragm sections, where
significant changes in amount and composition of the
ECM occur [24-26]. Figure 8 shows that in normal muscle
(A-D) ALP activity is localized at the endomysium, as is
evidenced by laminin staining, and that it is specifically
associated to cells and vascular structures surrounding
individual myofibers (Figure 8B). In mdx muscles, in con-
trast, ALP activity was found mainly within muscle fibers
as shown in Figure 8G-H. In both control and mdx muscle,
ALP activity was only found in restricted areas spread
throughout the tissue's cross section, either in the
endomysium surrounding a limited number of fibers, or
in a limited number of fiber groups, respectively. It is well
known that mdx muscles are under continuous degenera-
tion-regeneration cycles. To evaluate if the re-localization
of ALP in the diseased muscle was a consequence of the
formation of new fibers, we evaluated, by double staining,
the expression of both ALP and embryonic myosin (EM),
a marker of regenerating fibers. Figure 8(I-K) shows that
no strict spatial relationship between ALP activity and EM
positive fibers was found, as ALP(+)/EM(+), ALP(+)/EM(-
) and ALP(-)/EM(+) fibers were observed. Hence, the
increase and relocalization of ALP activity appears not to
be strictly linked to the formation of new fibers. However,
as different time courses in the expression of these two
markers, or the invasion of degenerating myofibers by
ALP(+) mononuclear cells are potential confounding fac-
tors for the interpretation of these results, we evaluated
this point further by studying the localization of ALP
activity in a model of damage-induced muscle regenera-
tion in control mice. This model shows more synchro-
nized skeletal muscle fibers formation than the mdx.
Expression of alkaline phosphatase by skeletal muscle fibers of the mdx mouse Figure 8
Expression of alkaline phosphatase by skeletal muscle fibers of the mdx mouse. Cross-sections of diaphragm from 
control (A-D) and mdx (E-K) 16 weeks old mice were stained with anti-laminin for basal lamina labeling and detected with 
rhodamine-conjugated secondary antibodies (B, F), and with ELF-97 detection kit for ALP activity (C, G). Merge of ALP (blue) 
and basal lamina staining (red) from the same fields is shown (D, H). In panel J, the merge from cross-sections of diaphragm 
from mdx 16 weeks old mice stained with anti-embryonic myosin detected with fluorescein-conjugated secondary antibodies 
(green) and with anti-laminin detected with rhodamine-conjugated secondary antibodies (red) is shown. Merge of ALP staining 
(blue) and basal lamina staining (red) from the same fields is shown (K). Phase contrast is shown at the left (A, E, I). Bar = 25 
μm.BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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Intramuscular injection of a 1.2% barium chloride solu-
tion induces necrosis of most skeletal muscle fibers of the
muscle in the first 3-4 days, which is followed by the com-
plete regeneration of the tissue [38]., Extensive remode-
ling of the ECM and changes in the expression of its
constituents occur during the process [39,28]. Figure 9
shows that, as was observed in the diaphragm, ALP activ-
ity is localized in some of the cells in the endomysium of
normal Tibialis Anterior muscle. Five and 15 days after
damage induction ALP activity is observed inside some of
the newly formed fibers. However, other regenerating fib-
ers from the same section at day five, positive for EM (Fig-
ure 9Finsert), were negative for ALP staining (Figure
9Hinsert). After 15 days of damage induction, EM expres-
sion was silent whereas ALP was still present inside some
fibers (Figure 9J-L) and after 28 days, ALP was again
mainly localized in the endomysium around individual
fibers (Figure 9P). These results suggest that under condi-
tions of tissue regeneration and ECM remodeling, ALP
expression is found in a subpopulation of regenerating
skeletal muscle fibers, in contrast to normal conditions,
where ALP activity in skeletal muscle is restricted to blood
vessels and some interstitial mononuclear cells in the
endomysium.
Discussion
Metaplasia, the conversion of one cell type into another,
has been suggested to be, at the molecular level, the con-
sequence of a change in the expression of key develop-
mental genes. In normal development, particular
combinations of these master genes are activated in each
embryo region following the expression of local inducing
signals. Postnatally, numerous examples of pathologic
metaplasia are known, but the underlying mechanisms
are poorly understood [40,41]. Metaplasias are nearly
always associated with situations of tissue regeneration, in
the absence of many of the signals that are present during
development. In this study we have demonstrated that
when myoblasts are cultured under conditions that affect
or modify ECM synthesis and assembly, an important and
Expression of alkaline phosphatase by skeletal muscle fibers during skeletal muscle regeneration Figure 9
Expression of alkaline phosphatase by skeletal muscle fibers during skeletal muscle regeneration. Cross-sections 
from control TA (A-D), and after five (E-H), fifteen (I-L) and twenty eight (M-P) days after barium chloride injection were 
stained with anti-embryonic myosin antibodies (B, F, J, N) and detected with fluorescein-conjugated secondary antibodies. 
Merge of embryonic myosin staining (green) and laminin staining (red), as described in Figure 7, is shown (C, G, K, O). Merge 
of ALP staining using ELF-97 detection kit (blue) and laminin staining (red) from the same fields is shown (D, H, L, P). Phase 
contrast is shown at the top (A, E, I, M). Different fields showing ALP-negative/embryonic myosin-positive fibers five days after 
the injection are presented as inserts (E-H). Bar = 25 μm.BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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significative increment in the expression of osteogenic
markers is observed. This occurs through a mechanism
that did not involve either the turn-off or turn-on of mas-
ter genes such as Myf-5, MyoD, myogenin or Cbfa-1. The
expression of these osteogenic markers was fully reverted
by the addition of an exogenous ECM. Furthermore, we
show that the ECM produced by myoblasts induced to
transdifferentiate into osteoblasts by BMP-2 treatment
was able to induce ALP activity in C2C12 myoblasts under
normal skeletal muscle differentiation conditions. Both
phenomena seem to be BMP-2 independent because the
induction of osteogenic markers was not inhibited by
competence with a soluble form of the BMP-2 receptor
ectodomain. These results suggest that signals arising
from the ECM induce the expression of osteogenic mark-
ers in myoblasts and emphasizes that a proper ECM is
required for correct skeletal muscle differentiation.
We have previously shown that skeletal muscle differenti-
ation was strongly inhibited under conditions where the
assembly of the ECM was affected by inhibitors of prote-
oglycans synthesis as sodium chlorate or β-D-xyloside
[11,12]. As a consequence of these treatments, a decrease
in focal adhesion kinase (FAK) phosphorylation was
observed [11]. This enzyme is activated upon interaction
of integrins with ECM constituents [42,43], but interfer-
ence of this interactions by the addition of RGDS peptides
affects normal skeletal muscle differentiation [10,11].
These observations indicate that a proper interaction and
signaling between cells and their environment is crucial
for adequate terminal differentiation.
Myoblasts are considered fully committed to muscle dif-
ferentiation due to the expression of the MRFs Myf-5 and
MyoD. We have previously shown that, under differentia-
tion conditions, proper expression and the nuclear locali-
zation of the MRF myogenin is not sufficient to drive a
successful myogenesis and that myoblasts-ECM interac-
tions are also required [11]. Here we show that when
myoblasts are grown in the absence of an appropriate
ECM, they express ALP and osteocalcin concomitant to
the expression of skeletal muscle determination-associ-
ated MRFs in the same cells. Therefore down-regulation of
MyoD or Myf-5 is not necessary for the appearance of an
osteoblastic-like phenotype. Furthermore we show that
the induction of Cbfa-1, a transcription factor essential for
osteogenesis [34,35], is not required for the initial expres-
sion of osteogenic markers in skeletal muscle cells. Our
observation is coincident with a previous report showing
that ALP induction after BMP-2 treatment of mouse myo-
genic cells preceded the down-regulation of MyoD expres-
sion, and that Cbfa-1 was normally expressed in
committed myogenic cells [36]. All these evidences sup-
port the proposed stock options model of differentiation
in skeletal muscle cells, where multiple determination
genes can be expressed and depending on the differentia-
tion-inducing signals the cells follow a terminal differen-
tiation pathway [36].
Several examples of transdifferentation, the conversion of
one differentiated cell type to another, are known in the
literature. Myoblasts can be made to transdifferentiate
into adipocytes after introduction of the transcription fac-
tors C/EBPα and peroxisome-proliferator-activated recep-
tor (PPAR)-γ [44]. It is also known that C2C12 myoblasts
can be converted to adipocytes after transfection with a
dominant-negative version of the transcription factor
TCF4 [45] and, as mentioned before, myoblasts can differ-
entiate into osteoblasts by BMP-2 treatment [17].
Although these observations suggest that muscle cells pre-
serve multi-potentiality, the exact requirements to achieve
the different phenotypes are still not clear. It is well
known that the MRF MyoD will convert several cell lines
into muscle [2], but, as discussed above, the forced expres-
sion of a particular gene might not be sufficient to drive
metaplasia without the proper environmental signals.
It has been shown that BMP-2/4 associated to the ECM are
essential for differentiation of osteoblastic cells [46]. The
fact that a soluble BMP-2 receptor ectodomain was unable
to inhibit the induction of osteogenic markers in myob-
lasts cultured in a deficient ECM indicates that we are in
presence of a different mechanism of osteogenic induc-
tion. Likely, changes in or the absence of some type of sig-
nals between the ECM and the cells, presumably through
integrins, are sufficient to trigger an osteoblastic pheno-
type. This concept is reinforced by the fact that the ECM
obtained from BMP-2 treated myoblasts was able to
induce ALP activity in normal myoblasts. If this is the
result of a new type of interaction between ECM and its
cell surface receptors or of the absence of some other inter-
actions requires further investigation. We have experi-
mental data that indicate that the proteoglycan
population synthesized by BMP-2 treated myoblasts is dif-
ferent in composition [47], but changes in other ECM
constituents may also have a role. It has been shown that
fibronectin supports the induction of ALP by ascorbic acid
in fibroblasts through its interaction with integrin α5β1,
whereas type I collagen fibrils cause the suppression of
ALP expression [48]. However, the possibility that BMP-2
may be inducing the expression of another osteogenic fac-
tor, such as BMP-7, which could be retained at the ECM
can not be excluded from our experiments.
Heterotopic bone formation within skeletal muscle is a
widely observed pathologic phenomenon, specially after
repeated trauma, but it is exacerbated in rare genetic dis-
eases such as Fibrodysplasia Ossificans Progressiva [45].
Osteoprogenitor cells are thought to reside in skeletal
muscle, although their identity in the tissue has not beenBMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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clearly determined [49]. On the other hand, it is known
that diseased muscles show increased ALP activity, as in
DMD, facioscapulohumeral dystrophy, polymyositis, etc.
[20,21,50]. As mdx  skeletal muscle is under constant
rounds of degeneration-regeneration and shows
enhanced ECM remodeling and deposition [24], we
thought it would be an appropriate model to evaluate
muscle ALP expression in an in vivo situation. We found
not only an increase in ALP activity but a relocalization of
the activity in dystrophic muscle, in contrast to normal
mice where the ALP was localized in scattered cells and
blood vessels around individual fibers. In mdx muscle ALP
activity was localized within muscle fibers that formed
small groups in the tissue. Expression of ALP activity by
skeletal muscle fibers had been previously reported in
DMD and congenital muscular dystrophy (CMD) muscle
biopsies, and its expression was suggested to be localized
in immature fibers [19]. We evaluated if there was a corre-
lation between the relocalization of ALP activity and the
formation of new muscle fibers. We found that although
some new muscle fibers, determined by the expression of
EM, were positive for ALP this was not always the case and
EM-positive fibers containing no ALP activity were also
found. When ALP expression during skeletal muscle
regeneration was evaluated, we also found ALP activity
within a small number of newly formed myotubes. ALP
expression in muscle fibers lasted for longer than the
expression of embryonic myosin, but one month after the
induction of damage ALP activity was found again local-
ized in the endomysium. It is known that during skeletal
muscle regeneration, fusing myoblasts are in contact with
a scaffold of remnant ECM from degenerated fibers before
they begin to synthesize their own ECM [38,39]. Consid-
ering that muscle tissue possess cells with osteogenic
potential that may also act as muscle precursor cells
[31,36] and our findings of ALP expression by endomysial
cells in normal muscle and ALP induction in groups of
fibers during muscle regeneration, it is interesting to spec-
ulate whether this phenomenon, if exacerbated by repeti-
tion in time or by impairment of its regulatory
mechanisms, may be related to heterotopic ossification.
The induction and relocalization of ALP activity found
under these two in vivo experimental conditions of skele-
tal muscle differentiation and ECM remodeling, extend
our observations of co-expression of differentiation mark-
ers for distinct lineages and suggest that they are perhaps
a consequence of a different interaction between the mus-
cle fibers and the surrounding ECM. This concept is sup-
ported by observations of ALP increase in the dystrophic
muscle of dy/dy mouse [22] and the presence of positive
myofibers for ALP in CMD [19], phenotypes that lack of
laminin α2 expression, so the normal interaction between
the basement membrane and the dystrophin-glycoprotein
complex or integrins is missing [23].
It is known from cell transplantation studies that cells of
different origins, such as bone marrow [51] and neural tis-
sue [52], can be incorporated into skeletal muscle. Fur-
thermore, muscle-derived cells different from satellite
cells, like the side population of dissociated muscle cells
or cells present in the interstitial space can differentiate
into muscle and hematopoietic cells or muscle and
endothelial cells, respectively [53-55]. In this work we
have shown that C2C12 myoblasts can be induced to
express osteogenic markers by signals from the ECM. The
mechanisms of metaplasia of these different cell popula-
tions are not clear, but what it might be critical in vivo is
the fact that these cells can become reprogrammed or pre-
pared to acquire different fates when surrounded by a par-
ticular environment.
Conclusion
The conversion of one cell type into another has been sug-
gested to be, at the molecular level, the consequence of
change(s) in the expression level of key developmental
genes. ECM has been shown to be essential during skeletal
muscle differentiation, through direct interaction with
myoblasts cell receptors. Myoblasts have the ability to dif-
ferentiate either to skeletal muscle or osteogenic lineage
depending of external stimuli. We explored the possibility
that ECM plays a role in the change of differentiation
pathway of skeletal muscle cells into osteogenic cells.
We show that the inhibition of proteoglycan sulfation by
sodium chlorate in myoblast cultures induces the expres-
sion of osteogenic lineage markers that can be prevented
by the addition of an exogenous ECM. ECM synthesized
by BMP-2 treated-myoblasts can also induce ALP in
myoblasts. This induction is mediated by BMP-2 inde-
pendent mechanisms in both cases. Expression of osteo-
genic markers does not affect the expression of muscle
commitment MRFs or the osteogenic determination gen
Cbfa-1. We finally show that in mdx and regenerating skel-
etal muscles, in vivo conditions of increased muscle ECM
turn-over and deposition, an induction and relocalization
of ALP was found from its expression by mononuclear
cells to a sub-group of regenerating muscle fibers.
These results suggest that signals arising from the ECM
induce the expression of osteogenic markers in muscle
cells by a mechanism independent of BMP-2 without
affecting the expression of key muscle or osteogenic deter-
mination genes. The induction and relocalization of ALP
was also observed in mdx and regenerating skeletal mus-
cles, in vivo conditions of increased muscle ECM deposi-
tion or turnover.
Methods
Cell Cultures
The mouse cell line C2C12 derived from regenerating adult
leg skeletal muscle (American Type Culture Collection)BMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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was grown and induced to differentiate as described
[56,57]. Sodium chlorate (final concentration 30 mM)
was added to the cultures at the time of plating. ECM gel
(Sigma Chem. Co., St. Louis, MO) was added after 2 days
of growth when the cells were switched to differentiation
medium. The medium was removed and 30 μl/cm2 of
ECM gel (diluted 1:5 in DME-Ham's F12) was added over
the cells and allowed to polymerize for 2 hours at 37°C.
Fresh differentiation medium was then added to the
plates containing the polymerized gel. BMP-2 was a gen-
erous gift from Genetic Institute (Cambridge, MA). Solu-
ble BMPR-IA corresponding to the extracellular domain of
mouse BMPR-IA was purchased from R& D Systems Inc.
(Minneapolis, MN), and was changed every two days at
the moment of medium renewal.
Primary cultures of myoblasts were obtained from the
hind limb muscles of 18-day-old rat embryos and cul-
tured as previously described [30]. 3 × 105 cells were
plated on 35 mm plastic tissue culture dishes coated with
1% gelatin and maintained in MEM-199 medium con-
taining 10% (v/v) horse serum, 10 units/ml penicillin and
100 g/ml streptomycin.
Animals and Experimental Muscle Injury
Parental strains of control (C57BL/10) and mdx
(C57BL10 mdx/mdx) mice were obtained from Jackson
Laboratories (Bar Harbor, ME, USA). The animals were
kept at room temperature with a 24 hour night-day cycle
and fed with pellets and water ad libitum. Injury of normal
Tibialis Anterior muscle (TA) was performed by barium-
chloride injection as described previously [28,38]. All pro-
tocols were conducted under strict accordance and with
the formal approval of the Animal Ethics Committee of
the P. Universidad Católica de Chile.
Fluorescence Microscopy
Cells to be immunostained were grown on glass cover-
slips. The medium was removed and the plates were
rinsed with PBS. For staining of extracellular proteins the
cells were incubated with primary antibodies for 1 hour at
4°C before fixation (perlecan 1:1500, fibronectin 1:100
and laminin 1:100). After rinsing, the cells were fixed with
3% paraformaldehyde for 30 minutes at room tempera-
ture. For staining of intracellular proteins the cells were
fixed with paraformaldehyde and then permeabilized
with 0.05% Triton X-100 in PBS. The cells were rinsed
with TSB (2% BSA in tris-buffered saline) and then incu-
bated for 1 hour at room temperature with the primary
antibodies (myogenin 1:50, MyoD 1:25, Myf-5 1:25). For
detection, permeabilized and not permeabilized cells
were incubated for 30 minutes at room temperature with
affinity purified fluorescein- or rhodamine-conjugated
secondary antibodies (PIERCE, Rockford, IL) diluted in
TSB. After immunofluorescence alkaline phosphatase
activity was detected using ELF-97 detection kit (Molecu-
lar Probes, Inc., Eugene, OR) according to the manufac-
turer directions. For nuclear staining, fixed cells were
incubated 5 minutes in 1 μg/ml Hoechst 33258 in PBS.
After rinsing, the cover slips were mounted with fluores-
cent mounting medium (Dako Corporation, CA). Fluo-
rescence was visualized using a Nikon Eclipse microscope
equipped for epifluorescence. Fields from the same exper-
iment were photographed and treated under identical
conditions. Polyclonal anti-mouse MyoD, anti-human
Myf-5 and anti-rat myogenin were from Santa Cruz Bio-
technology (Santa Cruz, CA). Polyclonal anti-human
fibronectin was purchased from Sigma and anti-mouse
perlecan was a generous gift from Dr. John R. Hassell.
For immunohistochemistry, cryostat sections (6 μm) of
control or mdx muscle, or TA harvested at different times
after BaCl2 injection were fixed for 20 minutes in 3% para-
formaldehyde in phosphate-buffered saline (PBS), pH
7.4, blocked with 3% BSA in PBS and incubated at 4°C
overnight with primary antibodies anti-embryonic
myosin (1:100) or/and anti-laminin (1:100). Sections
were then washed and incubated respectively with either
anti-mouse-FITC or anti-rabbit-TRITC conjugated second-
ary antibodies (all diluted 1:100, Pierce, IL) for 1 hour at
room temperature. Alkaline phosphatase activity was
detected as described before. Polyclonal anti-mouse lam-
inin was purchased from Sigma and monoclonal anti-
human embryonic myosin F1.652 was developed by Dr
H. Blau [58] and obtained from the Developmental Stud-
ies Hybridoma Bank, developed under the auspices of the
NICHD and maintained by The University of Iowa,
Department of Biological Sciences, Iowa City, IA.
Analysis of enzymatic activities
Myoblasts and myoblasts induced to differentiate were
washed twice with PBS, lysed by incubation with PBS con-
taining 0.1% Triton X-100 for 10 minutes at 4°C and har-
vested by scraping. ALP activity was quantified using ρ-
nitrophenyl phosphate in a pH 10.1 buffer as a substrate.
Formation of ρ-nitrophenol as a function of time at 37°C
was determined at 405 nm. CK activity was determined
using the CPK assay kit (Sigma Chem. Co., St. Louis, MO).
RT-PCR analyses
Total RNA was isolated from cell cultures using Trizol
(Invitrogen Corporation, Carlsbad, Ca). Equal amounts
of RNA were reverse-transcribed with Ready To-Go You-
Prime First-Strand Beads kit (Amersham Biosciences Inc.,
Piscataway, NJ) using oligo-dT as primers. For PCR the
paired primers for mouse osteocalcin used were CTC TGA
CCT CAC AGA TGC CAA/ACT TGC AGG GCA GAG AGA
GAG G (332 base pair); for mouse Cbfa-1 were TTT GCC
CTC ATC CTT CAC TCC/GAA AGC AAA TCT TGG GCA
ATA(541 base pair); for mouse myogenin were TCA CATBMC Cell Biology 2009, 10:73 http://www.biomedcentral.com/1471-2121/10/73
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AAG GCT AAC ACC CAG/GCA AAA CCA CAC AAT GCT
TAG T (503 base pair); and for mouse β-actin were ATG
GAT GAC GAT ATC GCT G/ATG AGG TAG TCT GTC AGG
T (568 base pair). Samples were denatured at 94°C for 5
minutes, followed by amplification rounds consisting of
denaturing at 94°C for 30 seconds, annealing at 60°C for
30 seconds and extension at 72°C for 30 seconds for 35
cycles and 72°C for 10 minutes.
Extracellular Matrix Preparation
C2C12 cells were induced to differentiate in 2.5 % horse
serum in the presence or absence of 5 nM BMP-2 on 6-
well plates (Costar, Corning, NY). At day 6 the cell layer
was detached with 5 mM EDTA in PBS at 37°C for 10
minutes [59,60]. Following cell removal the underlying
ECM was gently rinsed five times with cold PBS and used
immediately for cell plating.
DNA determination
DNA was determined in aliquots of cell extracts according
to the method of Labarca and Paigen [61]. Briefly, the flu-
orescence of Hoechst 33258 bound to DNA was measured
and aliquots compared to known concentrations of calf
thymus DNA, which was used as a standard.
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